ARTICLE SUMMARY:
An innovation friendly FDA led to more device approvals and faster review times this year.
S ome 91% of PMAs (premarket applications) and panel-track supplements were approved by FDA in fiscal 2017 (ended September), the second highest approval rate since 2001; the pinnacle to date was 95% in 2015.
